Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine

* At least a 1-year history of migraine with or without aura consistent with a diagnosis according to the International Classification of Headache Disorders, 3rd edition, (ICHD-3, 2018) * By history, the participant's migraines typically last between 4 and 72 hours if untreated or treated unsuccessfully and migraine episodes are separated by at least 48 hours of headache pain freedom * History of at least 2 migraine attacks per month in the 2 months prior to Screening * Have a sitting pulse rate ≥ 45 beats per minute (bpm) and ≤ 100 bpm during the vital sign assessment at the Screening Visit. Clinical site may perform a maximum of 2 repeats of vital sign measurements if the initial measurement is out of range. * Negative test results for benzoylecgonine (cocaine), methadone, barbiturates, amphetamines, benzodiazepines, cannabinoids, opiates, and phencyclidine at the Screening Visit and Day -1; unless explained by concomitant medication use (eg, opioids prescribed for migraine pain) * Participants willing to minimize the risk of inducing pregnancy for the duration of the clinical study and follow-up period

* Difficulty distinguishing migraine headache from tension-type or other headaches * Has a history of migraine aura with diplopia or impairment of level of consciousness, hemiplegic migraine, or retinal migraine as defined by ICHD-3 * Has a current diagnosis of new persistent daily headache, trigeminal autonomic cephalgia (eg, cluster headache), or painful cranial neuropathy as defined by ICHD-3 * Required hospital treatment of a migraine attack 3 or more times in the 6 months prior to Screening * Has a chronic non-headache pain condition requiring daily pain medication (with the exception of pregabalin) * Has clinically significant cardiovascular or cerebrovascular disease per the investigator's opinion * Previously participated in an investigational study of ubrogepant * Participation in any other clinical investigation using an experimental drug within 30 days prior to study intervention administration * Participation in a blood or plasma donation program within 60 or 30 days, respectively, prior to study intervention administration